Company / Current Liabilities
Enliven Therapeutics, Inc. Current Liabilities History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$15.9M
FY2024
5-year range
$6.2M / $25.9M
FY2020-FY2024
Trend
-38.5%
vs FY2023
Sector context
#195 of 213
Health Care
What the data says
Among 213 Health Care companies, Enliven Therapeutics, Inc. is in the top 8% for current liabilities. Increased from $10M to $16M over the past 2 years.
Based on SEC 10-K filings.
$16M in FY2024 with a 5-year CAGR of +30.5%.
Increased from $10M to $16M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +30.2%
- 5-Year CAGR
- +30.5%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 213This company $15.9M Sector average $1.6B
▼
-99.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +30.5%, indicating consistent growth.
- In FY2024, current liabilities decreased 38.5% year-over-year.
- Ranks #195 out of 213 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $15.9M | -38.5% |
| FY2023 | $25.9M | +166.5% |
| FY2022 | $9.7M | +34.7% |
| FY2021 | $7.2M | +15.4% |
| FY2020 | $6.2M | +48.8% |
| FY2019 | $4.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026